Compounds > pirfenidone

Page last updated: 2024-08-23

pirfenidone and Heart Failure

pirfenidone has been researched along with Heart Failure in 7 studies

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (14.29)	29.6817
2010's	2 (28.57)	24.3611
2020's	4 (57.14)	2.80

Authors

Authors	Studies
Hang, W; Li, N; Shu, H; Zhou, N	1
Cunnington, C; Dodd, S; Lewis, GA; McDonagh, T; Miller, CA; Rosala-Hallas, A; Schelbert, EB; Williams, SG	1
Cunnington, C; Dodd, S; Lewis, GA; McDonagh, T; Miller, CA; Rosala-Hallas, A; Schelbert, EB; Soltani, F; Williams, SG	1
Ahmed, FZ; Bedson, E; Clayton, D; Cooper, A; Cunnington, C; Dodd, S; Eccleson, H; Jimenez, BD; Lewis, GA; McDonagh, T; Miller, CA; Naish, JH; Russell, S; Schelbert, EB; Williams, SG; Williamson, PR	1
Ahmed, FZ; Bedson, E; Clayton, D; Cooper, A; Cunnington, C; Dodd, S; Eccleson, H; Jimenez, BD; Lewis, GA; McDonagh, T; Miller, CA; Naish, JH; Neubauer, S; Russell, S; Schelbert, EB; Viswesvaraiah, R; Williams, SG; Williamson, PR	1
Akazawa, H; Ishizu, T; Komuro, I; Lee, JK; Miwa, K; Naito, AT; Oka, T; Sakata, Y; Wang, Q; Yamagami, K	1
Ding, C; Everett, TH; Guerra, JM; Lee, KW; Olgin, JE; Rahmutula, D; Wilson, E	1

Trials

3 trial(s) available for pirfenidone and Heart Failure

Article	Year
Characteristics Associated With Growth Differentiation Factor 15 in Heart Failure With Preserved Ejection Fraction and the Impact of Pirfenidone. Journal of the American Heart Association, 2022, 07-19, Volume: 11, Issue:14 Topics: Fibrosis; Growth Differentiation Factor 15; Heart Failure; Humans; Male; Pyridones; Stroke Volume; Ventricular Function, Left	2022
Treatment Adherence in a Randomized Controlled Trial of Pirfenidone in HFpEF: Determinants and Impact on Efficacy. Journal of cardiac failure, 2023, Volume: 29, Issue:7 Topics: Fibrosis; Heart Failure; Humans; Stroke Volume; Treatment Adherence and Compliance; Ventricular Function, Left	2023
Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial. Nature medicine, 2021, Volume: 27, Issue:8 Topics: Aged; Female; Heart Failure; Humans; Male; Pyridones; Time Factors; Treatment Outcome	2021

Other Studies

4 other study(ies) available for pirfenidone and Heart Failure

Article	Year
Pirfenidone alleviates cardiac fibrosis induced by pressure overload via inhibiting TGF-β1/Smad3 signalling pathway. Journal of cellular and molecular medicine, 2022, Volume: 26, Issue:16 Topics: Animals; Fibrosis; Heart Failure; Male; Mice; Mice, Inbred C57BL; Myocardium; Pyridones; Smad3 Protein; Transforming Growth Factor beta1	2022
Pirfenidone in Heart Failure with Preserved Ejection Fraction-Rationale and Design of the PIROUETTE Trial. Cardiovascular drugs and therapy, 2019, Volume: 33, Issue:4 Topics: Adult; Aged; Double-Blind Method; Female; Fibrosis; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Pyridones; Stroke Volume; Ventricular Function, Left	2019
Pirfenidone exhibits cardioprotective effects by regulating myocardial fibrosis and vascular permeability in pressure-overloaded hearts. American journal of physiology. Heart and circulatory physiology, 2015, Aug-01, Volume: 309, Issue:3 Topics: Animals; Capillary Permeability; Cardiotonic Agents; Cells, Cultured; Claudin-5; Collagen Type I; Endothelial Cells; Fibroblasts; Fibrosis; Heart Failure; Heart Ventricles; Mice; Mice, Inbred C57BL; p38 Mitogen-Activated Protein Kinases; Pyridones	2015
Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation, 2006, Oct-17, Volume: 114, Issue:16 Topics: Animals; Atrial Fibrillation; Disease Models, Animal; Dogs; Heart Failure; Pyridones	2006